insights_auto
Why is LCTX up 2,06%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
0,96 US$
arrow_upward
+2,06%(+0,019) 1D
7 ოქტ, 11:54:05 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
0,94 US$
High
0,96 US$
Low
0,92 US$
Mkt. cap
241,54 მლნ.
Avg. vol.
1,35 მლნ.
Volume
476,88 ათ.
52-wk high
2,09 US$
52-wk low
0,88 US$
EPS
-0,14 US$
Beta
1,60
Shares outstanding
252,91 მლნ.
No. of employees
75
Open
0,94 US$
High
0,96 US$
Low
0,92 US$
Mkt. cap
241,54 მლნ.
Avg. vol.
1,35 მლნ.
Volume
476,88 ათ.
52-wk high
2,09 US$
52-wk low
0,88 US$
EPS
-0,14 US$
Beta
1,60
Shares outstanding
252,91 მლნ.
No. of employees
75
News stories
From web sources and news partners
Investing News Network
·
53 წუთის წინ
Snorkel AI Raises $350 Million to Help Push the Frontier: NYSE Content Update
Quartz
·
1 საათის წინ
Dow drops 451 points as Treasury yields hit 24-year highs
Seeking Alpha
·
1 საათის წინ
15 dividend stocks beating the S&P 500 as markets sit near record highs
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc